Examination of mechanism and the skin physiology change regarding the anti-inflammation action of minocycline in the skin disorders of the epithelium growth factor receptor inhibitor - Examination of mechanism and the skin physiology change regarding the anti-inflammation action of minocycline in the skin disorders of the epithelium growth factor receptor inhibitor

Wakayama medical university Third department of internal medicine,Oncology center0 个研究点目标入组 20 人开始时间: 2016年10月3日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)The patient with history of the EGFR inhibitor treatment. 2)The patient who applied steroid ointment and retinoid or a drug having retinoid-like action to the skin part that was measurement subject within two weeks before clinical trial start. 3)The patient who takes steroid and the minocycline internal use. 4)Complications of a wide range of skin or the patient who has the past. (burn, psoriasis, scleroderma etc.) 5)The patient who received drug-caused skin eruption within two weeks before clinical trial start. 6)A patient with the past of sensitivity to heparin resemblance material component preparation. 7)A patient with hemorrhagic blood disorder(hemophilia, more than grade3 thrombocytopenia, purpura) 8)The patient that it is expected that a few bleeding causes a serious result. 9)A case having serious complications(liver damages more than grade2, renal damage etc.). 10)The patient who internal use is difficult, and has severe diarrhea (more than grade2). 11)The patient with overlap cancer of the activity. 12)A nursing girl and the patient who may be pregnant. The patient who judges that a clinical study doctor (clinical study responsibility doctor,) is inadequate for reasons of others.

发起方

Wakayama medical university Third department of internal medicine,Oncology center